CL2012002762A1 - Método para pronosticar el riesgo de recurrencia de cáncer de próstata en un sujeto, que comprende determinar los niveles de expresión de por lo menos dos marcadores y la probabilidad predictiva en base a un nomograma de kattan; dispositivos; y kit. - Google Patents

Método para pronosticar el riesgo de recurrencia de cáncer de próstata en un sujeto, que comprende determinar los niveles de expresión de por lo menos dos marcadores y la probabilidad predictiva en base a un nomograma de kattan; dispositivos; y kit.

Info

Publication number
CL2012002762A1
CL2012002762A1 CL2012002762A CL2012002762A CL2012002762A1 CL 2012002762 A1 CL2012002762 A1 CL 2012002762A1 CL 2012002762 A CL2012002762 A CL 2012002762A CL 2012002762 A CL2012002762 A CL 2012002762A CL 2012002762 A1 CL2012002762 A1 CL 2012002762A1
Authority
CL
Chile
Prior art keywords
dispositives
recurrence
markers
kit
risk
Prior art date
Application number
CL2012002762A
Other languages
English (en)
Inventor
Dimitri Talantov
Yi Zhang
Yixin Wang
John F Palma
Timothy Jatkoe
Original Assignee
Veridex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veridex Llc filed Critical Veridex Llc
Publication of CL2012002762A1 publication Critical patent/CL2012002762A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Método para pronosticar el riesgo de recurrencia de cáncer de próstata en un sujeto, que comprende determinar los niveles de expresión de por lo menos dos marcadores y la probabilidad predictiva en base a un nomograma de Kattan; dispositivos; y kit.
CL2012002762A 2010-04-02 2012-10-02 Método para pronosticar el riesgo de recurrencia de cáncer de próstata en un sujeto, que comprende determinar los niveles de expresión de por lo menos dos marcadores y la probabilidad predictiva en base a un nomograma de kattan; dispositivos; y kit. CL2012002762A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32039810P 2010-04-02 2010-04-02

Publications (1)

Publication Number Publication Date
CL2012002762A1 true CL2012002762A1 (es) 2012-12-14

Family

ID=44712626

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002762A CL2012002762A1 (es) 2010-04-02 2012-10-02 Método para pronosticar el riesgo de recurrencia de cáncer de próstata en un sujeto, que comprende determinar los niveles de expresión de por lo menos dos marcadores y la probabilidad predictiva en base a un nomograma de kattan; dispositivos; y kit.

Country Status (12)

Country Link
EP (1) EP2553445B1 (es)
JP (1) JP2013524783A (es)
KR (1) KR101840624B1 (es)
CN (1) CN102939534A (es)
AR (1) AR080867A1 (es)
AU (1) AU2011235082B2 (es)
BR (1) BR112012025196A2 (es)
CA (1) CA2795242C (es)
CL (1) CL2012002762A1 (es)
IL (1) IL222167A (es)
MX (1) MX2012011481A (es)
WO (1) WO2011123615A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016191358A1 (en) 2015-05-22 2016-12-01 The Regents Of The University Of California Determining risk of prostate cancer recurrence
CN106198985B (zh) * 2016-08-31 2018-03-27 天津市泌尿外科研究所 用于检测去势抵抗性前列腺癌的elisa试剂盒及使用方法
CN106526185B (zh) * 2016-10-28 2018-03-30 拜尔康(天津)医药科技有限公司 用于检测去势抵抗性前列腺癌的elisa试剂盒及检测方法
WO2018101328A1 (ja) * 2016-11-29 2018-06-07 コニカミノルタ株式会社 診療補助情報の取得方法
CN107292127A (zh) * 2017-06-08 2017-10-24 南京高新生物医药公共服务平台有限公司 预测肺癌病人预后的基因表达分类器及其构建方法
KR102731352B1 (ko) * 2021-04-29 2024-11-18 연세대학교 산학협력단 위암의 예후 예측 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9609441D0 (en) 1996-05-04 1996-07-10 Zeneca Ltd Process
US5993388A (en) 1997-07-01 1999-11-30 Kattan; Michael W. Nomograms to aid in the treatment of prostatic cancer
US6409664B1 (en) 1997-07-01 2002-06-25 Michael W. Kattan Nomograms to aid in the treatment of prostatic cancer
GB9812768D0 (en) 1998-06-13 1998-08-12 Zeneca Ltd Methods
US20030054419A1 (en) * 2001-02-07 2003-03-20 Slawin Kevin M. Method to determine prognosis after therapy for prostate cancer
US20030235816A1 (en) * 2002-03-14 2003-12-25 Baylor College Of Medicine (By Slawin And Shariat) Method to determine outcome for patients with prostatic disease
EP1900824A1 (en) * 2006-09-14 2008-03-19 Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts Gene expression signature for the prognosis, diagnosis and therapy of prostate cancer and uses thereof
CA2668961A1 (en) * 2006-11-08 2008-05-15 The Regents Of The University Of Michigan Spink1 as a prostate cancer marker and uses thereof
US20080161203A1 (en) * 2006-12-27 2008-07-03 Su Chun-Lin Markers identified for liver fibrosis and cirrhosis and the microarray panel thereof
JP5513128B2 (ja) * 2007-01-19 2014-06-04 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ａｄｒｂ２癌マーカー
US20100297067A1 (en) * 2007-05-14 2010-11-25 The Johns Hopkins University Methylation markers for prostate cancer and methods of use
CN110079598A (zh) * 2007-10-23 2019-08-02 临床基因组学有限公司 诊断新生物的方法–ii
EP2806054A1 (en) * 2008-05-28 2014-11-26 Genomedx Biosciences Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
CN101469351B (zh) * 2008-08-29 2012-09-05 苏州福英基因科技有限公司 一种前列腺癌症早期诊断、转移、复发的综合检测试剂盒及应用

Also Published As

Publication number Publication date
EP2553445A4 (en) 2013-10-09
CN102939534A (zh) 2013-02-20
EP2553445B1 (en) 2016-03-30
KR20130023235A (ko) 2013-03-07
KR101840624B1 (ko) 2018-03-21
JP2013524783A (ja) 2013-06-20
WO2011123615A1 (en) 2011-10-06
CA2795242C (en) 2019-08-13
MX2012011481A (es) 2012-11-16
AR080867A1 (es) 2012-05-16
BR112012025196A2 (pt) 2017-03-28
AU2011235082A1 (en) 2012-10-18
EP2553445A1 (en) 2013-02-06
AU2011235082B2 (en) 2016-02-11
CA2795242A1 (en) 2011-10-06
IL222167A (en) 2017-11-30

Similar Documents

Publication Publication Date Title
CO7160023A2 (es) Métodos y aparatos para predecir riesgo de cáncer de próstata y volumen de glándula prostática
CL2012002762A1 (es) Método para pronosticar el riesgo de recurrencia de cáncer de próstata en un sujeto, que comprende determinar los niveles de expresión de por lo menos dos marcadores y la probabilidad predictiva en base a un nomograma de kattan; dispositivos; y kit.
EA201390762A1 (ru) Новые биомаркеры для предсказания исхода противораковой иммунотерапии
MX378293B (es) Metodos in vitro para correlacionar el nivel de st2 soluble y la eficiencia de terapia de ejercicio en un sujeto que tiene una enfermedad cardiovascular.
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
EA201270252A1 (ru) Консультативные системы и способы бурения с использованием целевых функций
UY31105A1 (es) Predicción pronóstica del melanoma
AR080872A1 (es) Biomarcadores para inhibidores de mdm2 para su uso en el tratamiento de enfermedad
MX358541B (es) Metodos para predecir el riesgo de desarrollar hipertension.
MX346973B (es) Anticuerpos especificos de tumores y usos para los mismos.
MX356986B (es) Metodo para detectar aductos de nucleosomas.
MX2013005067A (es) Receptor alfa de folato como marcador de diagnostico y pronostico para canceres que expresan receptor alfa de folato.
BR112018003969A2 (pt) plataforma de aplicativo de célula pequena
MX2013006601A (es) Dispositivo de iluminacion portatil con interfaz de usuario reconfigurable.
MX2013011334A (es) Biomarcadores para pronosticar sensibilidad a tratamientos contra el cancer.
EA201490533A1 (ru) Способы и композиции для определения статуса в отношении курения
MX2022002138A (es) Estandares de antigeno prostatico y sus usos.
MX2010005960A (es) Biomarcadores de braf.
MX2015004610A (es) Metodo para diagnostico, pronostico y tratamiento de metastasis de cancer de prostata usando c-maf.
MX2015010740A (es) Tratamiento del cancer basado en el estratificacion de anhidrasa carbonica ix (caix).
PE20150121A1 (es) Sistema y metodos para prediccion y evaluacion de riegos
AR089973A1 (es) Sistemas y metodos para la estimacion de tiempos de afloramiento de fluidos en sitios de pozos en produccion
AR085440A1 (es) Biomarcadores para predecir la recurrencia de metastasis de cancer colorrectal
EP2908136A4 (en) METHOD AND KIT FOR THE DISTINCTION BETWEEN A PROSTATE CARCINOMA AND BENIGNER PROSTATE HYPERPLASIA
MX2007013727A (es) Caracterizacion de cancer de prostata.